Centre for Big Data Research in Health Annual …...Centre for Big Data Research in Health, UNSW Sydney 2017 1 Director’s message I am pleased to share with you the achievements

Centre for Big Data Research in HealthAnnual Report 2017

Centre for Big Data Research in Health, UNSW Sydney

42017

Table of Contents

Director’s message ....................................................................................................................................... 1

Highlights 2017 ............................................................................................................................................. 2

Centre Overview ........................................................................................................................................... 6

Staff list 2017 ................................................................................................................................................ 8

Research Students 2017 ............................................................................................................................... 9

Research funding 2017 ............................................................................................................................... 11

Publications 2017 ....................................................................................................................................... 14

Invited conference presentations 2017 ......................................................................................................19


12017

Director’s messageI am pleased to share with you the achievements of the Centre for Big Data Research Health in 2017, our third full year of operation. It was an excellent year!

Particularly noteworthy was the appointment of three UNSW Scientia Fellows to the Centre: Associate Professor Georgina Chambers, Associate Professor Claire Vajdic and Dr Helga Zoega.

We had our first three PhD graduates: Dr Michael Falster, Dr Holger Moeller and Dr Andrea Schaffer. Dr Falster also received the Dean’s Award for Outstanding Contribution to Research by a Higher Degree Research Student and Dr Andrea Schaffer was awarded the Asian Conference on Pharmacoepidemiology “Rising Star Award”. Senior Research Fellow Dr Alys Havard was selected for UK Farr Institute’s Future Leaders in Health Data Science program.

We had strong grant success, with Centre researchers being awarded four NHMRC project grants, an NHMRC Centre of Research Excellence, a HCF Foundation Grant, a US National Institutes of Health (NIH) Grant and a Cooperative Research Centres Project (CRC-P) grant as chief investigators.

Development of Australia’s first Masters program in Health Data Science and continued throughout 2017, and we will welcome our first students in 2018. The MSc in Health Data Science will address an area of acute workforce shortage, and provide a pipeline into work in big data analytics for talented students from diverse backgrounds.

I very much look forward to reporting back on the launch of our teaching programs, as well as our burgeoning research programs, in next year’s report.


22017

Highlights 2017 Breast cancer study confirms the ‘Angelina Jolie’ effect

Actress Angelina Jolie’s 2013 announcement detailing her decision to undergo a mastectomy to reduce her risk of developing breast cancer likely inspired more women in English-speaking countries to do the same, according to a new study by researchers at UNSW Sydney’s Centre for Big Data Research in Health and Weill Cornell Medicine in New York, USA.

Using hospital discharge data from New York State and New South Wales from 2004-14 to examine trends in risk-reducing mastectomy (RRM), the researchers identified a significant increase in procedures starting in May 2013, three months after Jolie’s announcement.

They say their findings, published in Health Services Research, reveal that celebrities have the power to influence the healthcare decisions of the general public, and that healthcare professionals should leverage this effect by offering more information about treatment options, especially in regards to genetic testing results.

“This is an important area of research that healthcare providers and policy makers need to pay attention to,” said Dr Art Sedrakyan, a professor of healthcare policy and research at Weill Cornell Medicine. “If celebrities are going to act on genetic testing and announce their treatment choices, then we should get prepared on our end to assess public health impact.”

The study found that 20 months before Jolie’s announcement, there were an average of 3.3 bimonthly RRM cases per 1 million women in New York; 20 months after the announcement, there were an average of 6.3 bimonthly RRM cases per 1 million women in New York. Rates of RRM in New South Wales were similar.

A 2015 UK study showed an increase of RRM after Jolie’s announcement, but this new study shows correlation in two separate English-speaking countries, which also helps rule out local influences on RRM rates. It also validates previous studies that showed that singer Kylie Minogue’s 2005 breast cancer diagnosis led to an increase in breast imaging among Australian women age 25-44.

The researchers say that health professionals should be more proactive when celebrities announce personal health news, so that information about treatment, risk and cost is distributed clearly to the public.

“Both the ‘Kylie Effect’ and the ‘Jolie Effect’ demonstrate the power of celebrity illness and treatment to generate intense media coverage and change consumer behaviour,” Professor Louisa Jorm, Director of UNSW Sydney’s Centre for Big Data Research in Health, said.


32017

Study gives a better prediction of IVF success

Australian and New Zealand women who begin assisted reproductive technology (ART) ovarian stimulation treatment before the age of 30 have a 43.7% chance of a live birth after one cycle of treatment, with success rates increasing to between 69.2% and 92.8% by the seventh cycle, according to research published in the Medical Journal of Australia.

Almost 70,000 ART cycles are performed each year in Australia and New Zealand. Success rates per individual embryo transfer cycle attempt are generally reported, rather than from the overall perspective of a course of ART treatment.

The research, led by Associate Professor Georgina Chambers, director of the National Perinatal Epidemiology and Statistics Unit at UNSW, is the first to report cumulative live birth rates (CLBRs) based on Australian and New Zealand data for complete ovarian stimulation cycles.

“These estimates can be used when counselling women about their likelihood of having a baby using ART treatment, and to inform public policy,” Associate Professor Chambers and colleagues wrote.

The researchers followed 56,652 women who began ART treatment in Australia and New Zealand during 2009–2012, and followed them until 2014 or the first treatment-dependent live birth.

CLBRs and cycle-specific live birth rates were calculated for up to eight complete cycles of treatment, stratified by the age of the women.

The conservative CLBR assumed that women who discontinued treatment would have had no chance of a live birth had they continued treatment, while the optimal CLBR assumed that they would have had the same chance as women who continued treatment.

The range between the two estimates provides a reasonable appraisal of the probability of at least one live birth from repeated ART cycles.

“The cycle-specific live birth rate [the percentage of live births resulting from a specific cycle] decreased with increasing maternal age and with increasing cycle number. The highest rates were for the first complete cycle undertaken by women who commenced treatment before the age of 35 (43.7% for women under 30; 43.4% for women aged 30–34 years). The lowest live birth rates for the first complete cycle were for women aged 40–44 (10.7%) and 45 or more (1.4%).”

“CLBRs based on complete ART cycles are meaningful estimates of the success of ART treatment, reflecting contemporary clinical practice and encouraging safe embryo transfer practices,” the authors concluded.

“These estimates can be used when counselling prospective parents about the likelihood of treatment success, as well as for educating the public and informing policy on ART treatments.”


42017

Study spotlights Indigenous children and serious burns injuries

More Indigenous children are going to hospital in NSW with serious burns than non-Indigenous children and they are less likely to be treated in a hospital in a paediatric burns unit, despite needing more intensive treatment and a longer stay.A study led by the UNSW Centre for Big Data Research in Health and supported by researchers at The George Institute for Global Health investigated the differences in burn injuries in children, examining the cause of the injury, its location on the body, the total body surface affected (% TBSA), burn depth and length of hospital stay.

The proportion of Indigenous children with burns who presented with injuries affecting more than 10% TBSA was greater and the hospital stay was usually almost three days longer than non-Indigenous children.

A smaller proportion of Indigenous children with burns were treated in a hospital with a paediatric tertiary burns unit, fitting with previous studies that have shown Indigenous Australians experience inequities in access to medical services.

The first author on the paper published today in the Medical Journal of Australia, Holger Möller, says the higher proportion of Indigenous children presenting with burns affecting more than 10% TBSA is of particular concern.

“Burns can be among the most devastating of child injuries and can result in long-term physical and psychological impairment thus affecting the child’s development and future life,” he said.

“We could not assess the longer term outcomes of burn injury in this study and to date little is known about the long term outcomes, the post-discharge care, and the impact of care on functional outcomes in Aboriginal children.”

Scalds were the leading cause of burn injury to both Indigenous (47%) and non-Indigenous children (62%). There was a higher proportion of flame burns in Indigenous children, which may be partially explained by the higher number of Indigenous children living in rural and remote areas where there are more outdoor fires.

The study involved population-based cohort analysis of linked hospital and mortality data for 2000–2014, with 35,749 Indigenous and 1,088,938 non-Indigenous children aged under 13 years as participants.

The study was done with researchers from Neuroscience Research Australia, Australian National University, The George Institute for Global Health, Flinders University and the University of Wollongong.

Study co-author, Professor Rebecca Ivers, director of the Injury Division at The George Institute, is currently exploring the care of Aboriginal children with burns through a cohort study in Queensland, NSW, South Australia and the Northern Territory.The study is following children for at least two years post-burn in order to understand the impact and cost of burns. A roundtable is being planned for 2018 to develop a new model of care. The study utilises Indigenous research methodologies and three Aboriginal PhD students are working on the study.

“The study builds on previous understanding about burns in Aboriginal and Torres Strait Islander children but rather than just measuring inequality, will result in a new transformative model of care that meets the needs of patients and caregivers,” Professor Ivers said.

The study is governed by an Aboriginal advisory committee.


52017

A better way to estimate Australia’s future lifestyle-related cancers

A large collaborative study led by UNSW’s Centre for Big Data Research in Health applied a new and improved approach to comprehensive data from 370,000 Australians to estimate the numbers of cancers that could be avoided if Australians changed their lifestyles.

It showed that factors moderately associated with cancer risk but very prevalent in Australia, like excess body weight, can have a significant impact on the future burden of cancer.

Australia could avoid 74,000 cancers over the next 10 years if everyone was a healthy weight.

This information, published in the medical health journal BMJ Open, could transform national cancer prevention strategies, Dr Maarit Laaksonen says.“It would allow groups to consider, if we want to reduce a certain cancer in Australia, which risk factor should we best target?” Dr Laaksonen says.

“Also, we can look at sub-groups and ask, is the cancer burden more pronounced in men or women, in certain age groups, or socio-economic groups?

“It allows you to do all that and thus target prevention activities where they can do the most good, identifying the most vulnerable populations.”

The study also demonstrated how some risk factors are related, like smoking and excessive alcohol consumption.Of the tobacco- and alcohol-related cancers, 40,000 could be avoided in the next 10 years if no one smoked or drank more than two alcoholic drinks per day.

This figure was overestimated by 10,000 in calculations based on prior methods that assumed these risk factors acted independently, and did not account for dying from another health condition related to these factors.

These relationships should not be ignored to obtain a realistic estimate of the preventable numbers of future cancers.

Other areas planned for research include physical activity, diet and use of oral contraceptive and menopausal hormone therapy.

Dr Laaksonen says because these lifestyle-related risk factors are common to other conditions, like diabetes and cardiovascular disease, further work could also inform strategies to reduce the overall burden of chronic disease in the community.


62017

Centre Overview“Big data” refers to datasets whose size or complexity is beyond the ability of traditional methods and tools to capture, store, manage, and analyse. Big data in health and medicine are generated through operating the health system (e.g. medical service claims), clinical care (e.g. hospital records, primary care records), laboratories (e.g. imaging data, pathology records, genetic testing) and research studies (e.g. clinical trials, observational studies), to support disease prevention, control (e.g. disease notifications) and survivorship, and by individuals themselves (e.g. “life logging”). This type of ‘real-world’ data is growing rapidly and will continue to expand exponentially for the foreseeable future.

There is enormous potential to inform improvements in the effectiveness, safety and efficiency of health care by bringing these data together, and using them for research to understand the determinants of disease risk, target therapies to those who will benefit most, compare the effectiveness of alternative preventative and therapeutic interventions, and model the health and economic impacts of interventions and policies. Recognising this potential, research that will lead to “better models of care and services that improve outcomes, reduce disparities, increase efficiency and provide greater value” is listed first among the new national research priorities for health . Moreover, it is estimated that effective use of big data could also deliver reductions to national health care expenditure of around 8 percent which would translate to more than $11 billion annually in Australia.

The Centre for Big Data Research in Health (CBDRH) is a world-first research centre that is focused on delivering this value. The Centre supports UNSW Medicine’s Thematic Research model in which key research themes (Neuroscience, mental health and addiction; Infectious disease, immunity and inflammation; Cancer; Non-communicable diseases) are supported by cross-cutting enabling capabilities including ‘Big data in health’.

VisionThe power of “big data” is harnessed to transform the prevention and management of disease, and the delivery of health services.

MissionTo maximise the productive use of all possible sources of health big data in order to enhance the health and well being of Australians and the global community.

ValuesExcellence: Our research is scientifically rigorous and of high quality

Innovation: We use creative and novel approaches in study design, analysis techniques and reporting

Impact: Our high impact research benefits population health and the health care system

Leadership: We are influential in the health data science field and aim to be regarded as a world leader

Collaboration: We develop and maintain open and respectful relationships with research partners, the community, and each other

······· 1 http://www.science.gov.au/scienceGov/ScienceAndResearchPriorities/Pages/ThePriorities.aspx· 2 Manyika J, Chui M, Brown B, et al. Big data: The next frontier for innovation, competition, and productivity. San Francisco:

McKinsey Global Institute, 2011.


72017

Functions

Foster and develop innovation in health data science

Undertake high impact, high-quality and multi-disciplinary health and medical research using big data

Facilitate the rapid translation of research findings into health improvements and better value in health care

Build multi-disciplinary capacity in health research using big data

Promote public, clinical and policy awareness of the health and societal benefits of research using big data

Research Units

While the Centre has broad expertise that spans multiple health domains and the capability to address any health issue that can be informed through research using large-scale electronic data, it has a longstanding reputation as world leaders in thematic areas that correspond to its four internal research units:

Health Services and Outcomes Unit (HSO): undertakes research to identify variations and disparities in the use, outcomes and costs of health services, investigates the factors that drive these, and evaluates the outcomes of health policies and programs.

National Perinatal Epidemiology and Statistics Unit (NPESU): conducts national epidemiological, health services, policy and health economic research in reproductive, perinatal and maternal health.

Cancer Epidemiology Research Unit (CERU): performs genetic epidemiology and population-based health record linkage studies aimed at understanding the causes and consequences of cancer.

Medicines Policy Research Unit (MPRU): conducts research regarding the judicious use, safety, costs and cost-effectiveness of prescribed medicines.


82017

Staff list 2017Alys HavardAmy GibsonAndrea SchafferAndrew BlanceBich TranClaire VajdicDanielle TranGeorgina ChambersJan Zirk-SadowskiJennifer WalshKathleen FalsterKatie HarrisKylie-ann MallittLouisa JormLouise FrancisMaarit LaaksonenMaria ArriagaMarina van LeeuwenMark HanlyMelisa LitchfieldMichael FalsterMichele PartridgeNatasha DonnolleyOisin FitzgeraldOscar Perez ConchaPeter HullRepon PaulSabita RanaSallie-Anne PearsonSanja LujicSharon ChowStephanie ChoiWillings Botha


92017

Research Students 2017Bilal AhmedTopic: Utilisation of Antihypertensive Drugs During Pregnancy and the Risk of Adverse Outcomes for Mothers and their Children Primary Supervisor: Dr Alys HavardCo-Supervisor(s): Professor Louisa JormFunding source(s): International Postgraduate Research Scholarship (IPRS)

Maria ArriagaTopic: Lifestyle-related risk factors for cancer in AustraliaPrimary supervisor: Dr Maarit LaaksonenJoint Supervisor: A/Professor Claire VajdicFunding source(s): Australian Postgraduate Award, Translational Cancer Research Network (TCRN) PhD Scholarship Top-up Award

Jonathan BrettTopic: Developing a framework to quantify low value prescribing practices in routinely collected data Primary Supervisor: Professor Sallie PearsonCo-Supervisor(s): Professor Adam Elshaug, Professor Nicholas BuckleyFunding source(s): NHMRC Postgraduate Scholarship, NHMRC Centre for Research Excellence Medicines and Ageing Top-up Scholarship

Benjamin DanielsTopic: Big Data to Real World Evidence Around HER2-Targeted Cancer TherapiesPrimary Supervisor: Professor Sallie PearsonCo-Supervisor(s): Professor Nicholas BuckleyFunding source(s): Sydney Catalyst Scholarship, NHMRC Postgraduate Scholarship, NHMRC Centre for Research Excellence Medicines and Ageing Top-up Scholarship

Natasha DonnolleyTopic: Classifying maternity models of carePrimary Supervisors: Professor Michael Chapman, A/Professor Georgina Chambers (CBDRH)Co-supervisor(s):Professor Elizabeth Sullivan, Dr Kerryn Butler-Henderson

Michael Falster (PhD awarded)Topic: Understanding the roles of individuals, context and service availability in preventable hospitalisations in NSW, AustraliaPrimary Supervisor: Professor Louisa JormCo-Supervisor(s): Professor Alastair Leyland

Michael HennessyTopic: Cataract Surgery in NSW and relationship to health statusPrimary Supervisor: Professor Louisa JormCo-Supervisor(s): Prof Minas Coroneo, Dr Sieu Khuu, Dr Ian Harris, Dr Lisa Keay

Shamshad Jahan Topic: Educational & cognitive outcomes for Indigenous & non-Indigenous children born in NSW, Australia in 1997 - 2003: A population studyPrimary Supervisor: A/Professor Georgina ChambersCo-Supervisor(s): Professor Louisa JormFunding source(s): Jagdish & Lalitha Gupta Scholarship in Neonatal & Paediatric Research


102017

Ritu KunwaTopic: Effect of parental migration on healthcare seeking behaviour for common childhood illnesses and nutritional status of left behind children under 5 years of age in NepalPrimary supervisor: Dr David MuscatelloCo-Supervisor: A/Professor Claire VajdicFunding source(s): Australian Government Research Training Program Scholarship

Lise Lafferty (PhD Awarded)Topic: Social Capital of Indigenous and non-indigenous offendersPrimary Supervisors: A/Professor Georgina Chambers, Professor Tony ButlerCo-Supervisor(s): Dr Jill Guthrie (ANU)Funding source(s): NHMRC Aboriginal and/or Torres Strait Islander Health Research Postgraduate Scholarship

Evelyn LeeTopic: Embryo screening techniquesPrimary Supervisor: A/Professor Georgina ChambersCo-Supervisor(s): Dr Michael Costello

Mei Lin Lee Topic: The utilisation of Smoking Cessation Pharmacotherapies in pregnant smokersPrimary Supervisor: Dr Alys HavardCo-Supervisor(s): Dr Duong Tran, Professor Alec WelshFunding source(s): University International Postgraduate Award (UIPA)

Sanja LujicTopic: Comborbidity and Multiborbidity in New South Wales: Prevalence, Trajectories and Implications for Healthcare Utilization and CostsPrimary Supervisor: Professor Louisa JormCo-Supervisor(s): Professor Judy Simpson

Stella Settumba NalukwagoTopic: Economic Evaluation of Offender health programsPrimary Supervisor: Tony Butler (Kirby)Co-Supervisor(s): A/ Professor Georgina Chambers (CBDRH), Marian Shanahan (NDARC)Funding source(s): NHMRC Centre for Research Excellence in Offender Health Postgraduate Scholarship

Smriti RaichandTopic: Antidepressants use during pregnancy and their effects on mother and childPrimary Supervisor: Dr Alys HavardCo-Supervisor(s): Professor Sallie Pearson, Professor Nick BuckleyFunding source(s): Australian Postgraduate Award (APA), NHMRC Centre for Research Excellence Medicines and Ageing Top-up Scholarship

Andrea Schaffer (PhD awarded)Topic: Quality use of medicines in Australia: Using administrative databases to explore utilisation and best practice research methodsPrimary Supervisor: Professor Sallie PearsonCo-Supervisor(s): Professor Nicholas BuckleyFunding source(s): NHMRC Postgraduate Scholarship, NHMRC Centre for Research Excellence Medicines and Ageing Top-up Scholarship


112017

Research funding 2017 New Grants awarded 2017

1. Eades S, Sanson-Fisher R, McAullay D, Ivers R, Jorm L, Bryant J, Goldfeld S, Oldmeadow C, Searles A. Aboriginal child and adolescent health improvement through Aboriginal leadership and collaborative research teams. NHMRC Centre for Research Excellence in Population Health Research 2017 ($2,499,589).

2. Woodward M, Jorm L, Redfern J, Havard A, Randall D, Peters S. Sex disparities in management of myocardial infarction. NHMRC Project Grant 2018 ($615,585).

3. Graves S, Pratt N, Inacio M, de Steiger R, Harris I, Ackerman I, Jorm L. Enhancing joint replacement outcomes through national data linkage. NHMRC Project Grant 2018 ($765,349).

4. Degenhardt L, Pearson S, Dobbins T, Gisev N, Currow D, Blyth F, Larney S, Dunlop A, Mattick R, Wilson A. Combating escalating harms associated with pharmaceutical opioid use. NHMRC Project Grant 2018-2021 ($925,000).

5. Gandhi M, MacManus M, Seymour J, Vajdic C, Fink L, Green M, Cheah C, Trau M, Korbie D. NHMRC Project Grant - Application Title: Integrating immunity and genetics in Follicular Lymphoma to establish a prognostic score fit for the modern era. NHMRC Project Grant 2018-2021 ($1,377,174).

6. Prospection Pty Ltd, The University of New South Wales (Jorm L, Pearson S), Janssen-Cilag Pty Ltd. A big health data analytics and insights platform for the MTP sector. Australian Government Cooperative Research Centre Projects (CRC-P) 2017 ($1,948,008).

7. Korda R, Banks E, Lynch J, Jorm L, Lovett R, Calabria B. Whole-of-population linked data: strengthening the evidence to drive improvement in health and health care in Australia. NHMRC Partnership Project Grant 2017 ($1,130,376).

8. Sachdev P, Ganguli M, Jorm L, Brodaty H, Peterson R, Lipton R, Ritchie K, Kim K. COhort Studies of Memory International Consortium (COSMIC). NIH Project Grant 2017 (US$2,600,000)

9. Jorm L, Blance A, Churches T, Parker R, Sisson S, Pearson S, Shepherd J, Straka P, Lujic S. Health Data Analytics Training Materials. Commonwealth Department of Health 2017 ($1,294,451).

10. Lui K, Haslam R, Chambers G, Gill A, Callander I, Cruz M, Tarnow-Mordi. Using a clinical registry to reduce variation in clinical outcomes in Neonatal Intensive Care Unit. HCF Foundation 2017. ($211,000)

Ongoing Grants 2017

1. Chambers G, Jorm L, Norman R, Lui K, Havard A. Medically assisted fertility treatment and infant outcomes: The role of IVF (in vitro fertilisation), ovulation induction and subfertility. NHMRC Project Grant 2017 ($463,000).

2. Pearse J, Jorm L, Hall J, Mazevska D, McElduff P, Pearson S, Falster M, van Gool K. Evaluation of the Health Care Homes model of care. Commonwealth Department of Health 2016 ($3,135,369).

3. Jorm L, Ainsworth M, Barton M, Chambers G, Churches T, Close J, Cooke R, Degenhardt L, Dobbins T, Dore G, Harris I, Hayen A, Ledger W, Liaw S, Mackies J, Moses D, Pearson S, Rubin G, Sachdev P, Saxena M, Vajdic C. UNSW Medicine E-Research Institutional Cloud (ERICA). Major Research Equipment and Infrastructure Initiative (MREII). UNSW Sydney ($780,800).

4. Chambers G, Donnolley N, Homer C, Nicholl M. Evaluation of maternity care using ICHOM standards and MaCCS. HCF Research Foundation ($218,525).

5. Chambers, G. Australian and New Zeland Assisted Reproduction Database (AZNARD). Fertility Society of Australia (FSA).


122017

6. Trollor J, Vajdic C, Lennox N, Moorin R, Reppermund S. Understanding health service system needs for people with intellectual disability. NHMRC Project Grant 2017 ($1,216,388).

7. Jordon S, Pearson S, Pandeya N, Stewart L, Coory M, Spilsbury K, Donovan P. IMPROVE - Investigating Medication re-Purposing to Reduce risk of OVarian cancer and Extend survival. NHMRC Project Grant 2017 ($430,196).

8. Miller P, Egerton-Warburton D, Shakeshaft A, Caldicott D, Staiger P, Havard A, Doran C, Baker T, Weiland T, Bowe S. Driving Change: Using emergency department data to reduce alcohol-related harm. NHMRC Partnership Grant 2016 ($3,596,826).

9. Brodaty H, Valenzuela M, Sachdev P, McNeil J, Maeder A, Lautenschlager N, Jorm L, Fiatarone Singh M, Anstey K, Andrews G. Maintain Your Brain. NHMRC Dementia Team Grant 2015 ($6,467,016).

10. Havard A. The risk of cardiovascular events, seizures and psychiatric conditions associated with use of smoking cessation pharmacotherapies: a population-based study. National Heart Foundation Future Leader Fellowship 2015 ($519,925).

11. Havard A, Jorm L, Preen D, Daube M, Kemp A, Einarsdottir K, Randall D. Pharmacotherapy for smoking cessation during pregnancy and the inter-pregnancy period: a population-based cohort study. NHMRC Project Grant 2012 ($620,950).

12. McNamara B, Eades S, Jorm L, Preen D, Jones J, Joshy G, Gubhaju L, Shepherd C, McCaullay D. Defying the odds’: Exploring the impact of perinatal outcomes, maternal social and health outcomes and level of culturally appropriate service availability on the health of Western Australian Aboriginal infants and children. NHMRC Project Grant 2014 ($634,886).

13. Jorm LR, Falster K, Eades S, Lynch J, Banks E, Brownell M, Craven R, Einarsdottir K, Randall D. Seeding success: identifying factors that contribute to positive early childhood health and development in Aboriginal children. NHMRC Project Grant 2013 ($672,081).

14. Redman S, Jorm L, Green S, D’Este K, Louviere J, Frew D, Shakeshaft A, Davies H. Centre for Informing Policy through Evidence from Research (CIPHER). NHMRC Centre for Research Excellence in Health Services Research 2011 ($2,500,000).

15. Reath J, Gunasekera H, Leach A, Abbott P, Askew D, Girosi F, Kong K, Bond C, Hu W. (AIs: Morris P, Peiris D, Spurling G, Lujic S, Usherwood T). Watchful waiting in Aboriginal and Torres Strait Islander children with acute otitis media (WATCH). NHMRC Project Grant 2013 ($1,640,326).

16. Chambers G, Norman R, Ledger W, Shanahan M, Raymer J. Accountable fertility treatment: An evidenced-based framework for the provision of cost-effective, patient-centred fertility treatment in Australia. NHMRC Project Grant 2016 ($423,312).

17. Chambers, G. ART report. Fertility Society of Australia (FSA) 2016-2019 .

18. Chambers C. Assisted reproductive technology in New Zealand 2015 report. New Zealand Ministry of Health.

19. Chambers C. National Maternity Data Development Project (NMDDP) Phase 2. Australian Institute of Health and Welfare (AIHW) 2015-2018.

20. Chambers C. National Maternity Data Development; Maternity Models of Care Data Collection Tool. Australian Institute of Health and Welfare (AIHW) 2015-2017.

21. Chambers C. Population Burden analysis of low birth weight by indigenous status and IECD birthweight, antenatal care and smoking data. Australian Institute of Health and Welfare (AIHW).

22. Chambers C. Australian Fertility Medicine Foundation Donation: 2015-2016.

23. Vajdic C, Ward R, Thom J, Applegate T, Lamoury F, Ainsworth M, Hettiaratchi A. Automated biospecimen preparation and assay instrument (QIAsymphony SP). UNSW Australia Major Research Equipment and Infrastructure Initiative 2015 ($186,716).

24. Laaksonen M, Canfell K, Vajdic C, MacInnis. Population-level relevance of risk factors for cancer. NHMRC Project Grant ($310,292).


132017

25. Vajdic C, Severi G, McDonald K, Nowak A, Rosenthal D, Drummond K, Walker D, Jeffree R. Risk and prognostic factors for glioma in Australia. Cancer Australia Priority-driven Collaborative Research Scheme 2012 ($600,000).

26. Giles G, Vajdic CM, Prince M, Harrison S, Joshua D, Campbell L. The epidemiology of multiple myeloma in Australia (EMMA). NHMRC Project Grant 2012 ($1,445,512).

27. Vajdic C, Giles G, Seymour J, Miliken S, Benke G, Cozen W. A population-based family study of follicular lymphoma. NHMRC Project Grant 2011 ($1,619,364).

28. Vajdic C, Pearson S, Dobbins T. Health service utilization and risk factors for cancer of unknown primary. Cancer Institute NSW Cancer Epidemiology Linkage Program Grant 2011 ($304,270).

29. Elshaug E, Pearson S, Scott I. Measuring low-value health care for targeted policy action. NHMRC Project Grant 2016 ($806,176)

30. Pearson S-A, Schneider C, Karanges EA, McGregor IS, Buckley N, McLachlan A, Wilson F, Marshall N, Hunt G, Allsop D, Bowen M, Hunt, C, Russell J, Abbott M, Lintzeris N. From ‘BIG DATA’ to evidence: Post-market surveillance of psychotropic medicines in Australia. University of Sydney BMRI SPARC Funding 2016 ($49,700).

31. McLachlan A, Pearson S, Banks E, Preen D, Le Couteur D, Dobbins T, Etherton-Beer C, Buckley N, Viney R, Henry D. Centre of Research Excellence in Medicines and Ageing. NHMRC Centre of Research Excellence 2014 ($2,446,505).

32. Lipwoth W, Kerridge I, Salkeld G, Olver D, Isaacs D, Pearson S. Improving decisions about the funding of high cost cancer medicines in Australia. NHMRC Project Grant 2015 ($549,492).

33. Travena L, Emery J, Dowie J, Pearson S, Rothwell P, Pignone M, Olver I, Tifler G, Barnes E. Should I take low dose aspirin? The ‘Optimise’ decision aid study. NHMRC Project Grant 2014 ($424,115).

34. Schaffer A. Post-market surveillance of medicine-related adverse events: Using linked administrative databases to explore outcomes and best-practice research methods. NHMRC Postgraduate Scholarship 2014.

35. Brett J. Measuring the extent and consequences of ‘low value’ prescribing. NHMRC Postgraduate Scholarship 2015.

36. Daniels B. Big data to real-world evidence: Informing pharmaceutical policy decisions around targeted cancer medicines. NHMRC Postgraduate Scholarship 2015.

37. Pearson S. Post-market surveillance of cancer medicines: Generating evidence for clinical policy practice using linked health administrative data. Cancer Institute NSW Career Development Fellowship 2013 ($150,000).

38. Vajdic C, Pearson S, Dobbins T. Health service utilization and risk factors for cancer of unknown primary. Cancer Institute NSW Cancer Epidemiology Linkage Program Grant 2011 ($300,000).

39. Pearson S, Ward R, Dobbins T, Lu C. The use and impact of high cost targeted cancer medicines: theory and reality. Cancer Australia and National Breast Cancer Foundation Project Grant 2013 ($399,107).

40. Abrahamowicz M (Pearson S international investigator). Drug Safety and Effectiveness network Collaborating Centre. Canadian Institute of Health Research 2014 ($1,250,000).

41. Pearson S, Elshaug A, Wilson A, Salkeld G. Low value medical services and prescribing practices in cancer care: towards a comprehensive framework for quantifying waste in Australia and beyond. Cancer SPARC Implementation Scheme 2015 ($150,000).

42. Pearson S, Schneider C, Karanges E, McGregor I, Buckley N. From ‘BIG DATA’ to evidence: Post-market surveillance of psychotropic medicines in Australia. BMRI SPARC Implementation Scheme 2015 ($50,000).

43. Pearson S, Charles C. Do changes in chemotherapy dose and increased toxicity explain poorer survival outcomes in advanced cancer patients with systemic inflammation? Sydney Catalyst Seed Funding Grant 2015 ($50,000).

44. Blanch B. Prescribed medicine misuse in Australia. University of Sydney Postgraduate Award 2013.


142017

Publications 2017Papers published in peer-reviewed journals

1. Chambers GM, Randall S, Mihalopoulos C, Reilly N, Sullivan EA, Highet N, et al. Mental health consultations in the perinatal period: a cost-analysis of Medicare services provided to women during a period of intense mental health reform in Australia. Aust Health Rev. 2017 Dec. doi: 10.1071/AH17118. [Epub ahead of print].

2. Schaffer AL, Buckley NA, Pearson SA. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1465-1473. doi: 10.1002/pds.4342. [Epub 2017 Oct 25].

3. Lee E, Chambers GM, Hale L, Illingworth P, Wilton L. Assisted reproductive technology (ART) cumulative live birth rates following preimplantation genetic diagnosis for aneuploidy (PGD-A) or morphological assessment of embryos: A cohort analysis. Aust N Z J Obstet Gynaecol. 2017 Dec. doi: 10.1111/ajo.12756. [Epub ahead of print]

4. Vajdic CM, Laaksonen MA. Commentary: Unusual pancreatic cancer incidence and mortality patterns. Int J Epidemiol. 2017 Dec;46(6):1772-1773. doi: 10.1093/ije/dyx142.

5. Harris CA, Daniels BJ, Ward RL, Pearson SA. Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012). Public Health Res Pract. 2017 Dec;27(5):e2751744. doi.org/10.17061/phrp2751744.

6. Tan SYS, O’Neill S, Goldstein D, Ward RL, Daniels B, Vajdic CM. Predictors of care for patients with cancer of unknown primary site in three Australian hospitals. Asia Pac J Clin Oncol. 2017 Nov. doi: 10.1111/ajco.12815. [Epub ahead of print].

7. Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak DB, Pearson S, et al. Trends in chlamydia and gonorrhoea testing and positivity in Western Australian Aboriginal and non-Aboriginal women 2001-2013: A population-based cohort study. Sex Health. 2017 Nov;14(6):574-580. doi: 10.1071/SH16207.

8. Bernatsky S, García HAV, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, …., Vajdic CM, et al. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Sci Med. 2017 Nov;4(1):e000187. doi: 10.1136/lupus-2016-000187. eCollection 2017.

9. Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, Nassir A, McLachlan AJ, Pearson SA. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol. 2017 Nov;83(11):2581-8. doi: 10.1111/bcp.13369. [Epub 2017 Aug 16].

10. Homaira N, Briggs N, Pardy C, Hanly M, Oei JL, Hilder L, et al. Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study. BMJ Open. 2017 Nov;7(11):e017936. doi: 10.1136/bmjopen-2017-017936.

11. Moller H, Falster K, Ivers R, Clapham K, Harvey L, Jorm L. High rates of hospitalised burn injury in Indigenous children living in remote areas: a population data linkage study. Aust N Z J Public Health. 2017 Nov 22. doi:10.1111/1753-6405.12729.

12. Hanly M, Falster K, Chambers G, Lynch J, Banks E, Homaira N, Brownell M, Eades S, Jorm L. Gestational Age and Child Development at Age Five in a Population-Based Cohort of Australian Aboriginal and Non-Aboriginal Children. Paediatr Perinat Epidemiol. 2017 Nov 22. doi: 10.1111/ppe.12426. [Epub ahead of print].

13. Brett J, Karanges EA, Daniels B, Buckley NA, Schneider C, Nassir A, Zoega H, McLachlan AJ, Pearson SA. Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry. 2017 Oct;51(10):990-999. doi: 10.1177/0004867417721018. [Epub 2017 Jul 31].


152017

14. Roxburgh A, Hall WD, Dobbins T, Gisev N, Burns L, Pearson S, et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend. 2017 Oct;179:291-298. doi: 10.1016/j.drugalcdep.2017.07.018. [Epub 2017 Aug 14].

15. Chalmers K, Pearson SA, Elshaug AG. Quantifying low-value care: A patient-centric versus service centric lens. BMJ Qual Saf. 2017 Oct;26(10):855-858. doi: 10.1136/bmjqs-2017-006678. [Epub 2017 Aug 19].

16. Falster K, Jorgensen M, Hanly M, Banks E, Brownell M, Eades S, et al, Jorm L. Data Resource Profile: Seeding Success: a cross-sectoral data resource for early childhood health and development research in Australian Aboriginal and non-Aboriginal children. Int J Epidemiol. 2017 Oct;46(5):1365-1366j. doi: 10.1093/ije/dyx051.

17. Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, ……Litchfield M, ……. Pearson SA,… et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017 Oct;27(10):1064-1076. doi: 10.1016/j.euroneuro.2017.07.001. Epub 2017 Jul 27.

18. Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS One. 2017 Oct 10;12(10):e0184360. doi: 10.1371/journal.pone.0184360. eCollection 2017.

19. Mao J, Jorm L, Sedrakyan A. Trends in Use of Risk-Reducing Mastectomy in a Context of Celebrity Decisions and Media Coverage: An Observational Study in the United States and Australia. Health Serv Res. 2017 Sep. doi: 10.1111/1475-6773.12774. [Epub ahead of print].

20. Falster MO, Jorm LR, Leyland AH. Using Weighted Hospital Service Area Networks to Explore Variation in Preventable Hospitalization. Health Serv Res. 2017 Sep 22. doi:10.1111/1475-6773.12777.

21. Gidding HF, McCallum L, Fathima P, Snelling TL, Liu B, de Klerk N, Blyth CC, Sheppeard V, Andrews RM, Jorm L, McIntyre P, Moore HC. Probabilistic linkage of national immunisation and state-based health records for a cohort of 1.9 million births to evaluate Australia’s childhood immunization program. IJPDS. 2017 Sept;2(1). doi: 10.23889/ijpds.v2i1.406.

22. Donnolley NR, Chambers GM, Butler-Henderson KA, Chapman MG, Sullivan EA. More than a name: Heterogeneity in characteristics of models of maternity care reported from the Australian Maternity Care Classification System validation study. Women Birth. 2017 Aug;30(4):332-41. doi: 10.1016/j.wombi.2017.01.005. [Epub 2017 Feb 4].

23. Havard A, Tran DT, Kemp-Casey A, Einarsdóttir K, Preen DB, Jorm LR. Tobacco policy reform and population-wide antismoking activities in Australia: the impact on smoking during pregnancy. Tob Control. 2017 Aug. pii: tobaccocontrol-2017-053715. doi: 10.1136/tobaccocontrol-2017-053715. [Epub ahead of print].

24. Lujic S, Simpson JM, Zwar N, Hosseinzadeh H, Jorm L. Multimorbidity in Australia: Comparing estimates derived using administrative data sources and survey data. PLoS One. 2017 Aug;12(8):e0183817. doi: 10.1371/journal.pone.0183817. eCollection 2017.

25. Settumba SN, Chambers GM, Shanahan M, Schofield P, Butler T. Are We Getting Value for Money from Behavioral Interventions for Offenders? A Research Note Reviewing the Economic Evaluation Literature. Am J Crim Just. 2017 Aug;1-21.

26. Tran DT, Gibson A, Randall D, Havard A, Byrne M, Robinson M, Lawler A, Jorm LR. Compliance with telephone triage advice among adults aged 45 years and older: An Australian data linkage study. BMC Health Serv Res. 2017 Aug 1;17(1):512. doi: 10.1186/s12913-017-2458-y.

27. Abbott P, Magin P, Lujic S, Hu W. Supporting continuity of care between prison and the community for women in prison: A medical record review. Aust Health Rev. 2017 Jul;41(3):268-76. doi: 10.1071/AH16007.

28. Chambers GM, Paul RC, Harris K, Fitzgerald O, Boothroyd CV, Rombauts L, Chapman M, Jorm L. Assisted reproductive technology in Australia and New Zealand: Cumulative live birth rates as measures of success. Med J Aust. 2017 Jul;207(3):114-8. doi: 10.5694/mja16.01435.


162017

29. Reilly N, Black E, Chambers GM, Schmied V, Matthey S, Farrell J, et al. Study protocol for a comparative effectiveness trial of two models of perinatal integrated psychosocial assessment: The PIPA project. BMC Pregnancy Childbirth. 2017 Jul;17(1):236. doi: 10.1186/s12884-017-1354-0.

30. Tran DT, Havard A, Jorm LR. Data cleaning and management protocols for linked perinatal research data: A good practice example from the Smoking MUMS (Maternal Use of Medications and Safety) Study. BMC Med Res Methodol. 2017 Jul;17(1):97. doi: 10.1186/s12874-017-0385-6.

31. Arriaga ME, Vajdic CM, Canfell K, Macinnis R, Hull P, Magliano DJ, …. et al, Laaksonen MA. The burden of cancer attributable to modifiable risk factors: The Australian cancer-PAF cohort consortium. BMJ Open. 2017 Jun;7(6):e016178. Doi: 10.1136/bmjopen-2017-016178.

32. Reeve R, Srasuebkul P, Langton J, Haas M, Viney R, Pearson S. Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history. BMC Palliat Care. 2017 Jun;17(1):1. doi: 10.1186/s12904-017-0213-0.

33. Abelson JS, Michelassi F, Sun T, Mao J, Milsom J, Samstein B, et al. Simultaneous Resection for Synchronous Colorectal Liver Metastasis: the New Standard of Care? J Gastrointest Surg. 2017 Jun;21(6):975-82. doi: 10.1007/s11605-017-3422-1. [Epub 2017 Apr].

34. Brett J, Elshaug AG, Bhatia RS, Chalmers K, Badgery-Parker T, Pearson SA. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: An Australian case study. Implement Sci. 2017 May;12(1):58. doi: 10.1186/s13012-017-0585-9.

35. Möller H, Harvey L, Falster K, Ivers R, Clapham KF, Jorm L. Indigenous and non-indigenous Australian children hospitalised for burn injuries: A population data linkage study. Med J Aust. 2017 May;206(9):392-397.

36. Nielsen S, Gisev N, Bruno R, Hall W, Cohen M, Larance B, …, Pearson S, et al. Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiol Drug Saf. 2017 May;26(5):587-591. doi: 10.1002/pds.4168. [Epub 2017 Jan 19].

37. Mallitt KA, McNab J, Hughes R, Fernyhough J, Paterson J, O’Halloran D. Reducing emergency department presentations among chronically ill patients in Western Sydney: A key role for coordinated primary care. Aust J Prim Health. 2017 May;23(2):140-146. doi: 10.1071/PY16012.

38. Karapetis CS, Guccione L, Tattersall MHN, Gooden H, Vajdic CM, Lambert S, et al. Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. Intern Med J. 2017 Apr;47(4):408-414. doi: 10.1111/imj.13373.

39. Du W, Pearson SA, Buckley NA, Day C, Banks E. Diagnosis-based and external cause-based criteria to identify adverse drug reactions in hospital ICD-coded data: Application to an Australian population-based study. Public Health Res Pract. 2017 Apr;27(2). pii: 2721716. doi: 10.17061/phrp2721716.

40. Zwi K, Morton N, Woodland L, Mallitt KA, Palasanthiran P. Screening and primary care access for newly arrived paediatric refugees in regional Australia: A 5 year cross-sectional analysis (2007-12). J Trop Pediatr. 2017 Apr;63(2):109-117. doi: 10.1093/tropej/fmw059.

41. Morley KC, Logge W, Pearson SA, Baillie A, Haber PS. Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. J Subst Abuse Treat. 2017 Mar;74:23-25. doi: 10.1016/j.jsat.2016.12.004. [Epub 2016 Dec 23].

42. Skinner A, Havard A, Tran DT, Jorm LR. Access to Subsidized Smoking Cessation Medications by Australian Smokers Aged 45 Years and Older: A Population-Based Cohort Study. Nicotine Tob Res. 2017 Mar 1;19(3):342-350. doi:10.1093/ntr/ntw202.

43. Gibson A, Randall D, Tran DT, Byrne M, Lawler A, Havard A, Robinson M, Jorm LR. Emergency Department Attendance after Telephone Triage: A Population-Based Data Linkage Study. Health Serv Res. 2017 Mar 29. doi.org/10.1111/1475-6773.12692. [Epub ahead of print].

44. Oei JL, Melhuish E, Uebel H, Azzam N, Breen C, Burns L, Hilder L, et al. Neonatal abstinence syndrome and high school performance. Pediatrics. 2017 Feb;139(2). pii: e20162651. doi: 10.1542/peds.2016-2651. [Epub 2017 Jan 16].


172017

45. Knight A, Havard A, Shakeshaft A, Maple M, Snijder M, Shakeshaft B. The feasibility of embedding data collection into the routine service delivery of a multi-component program for high-risk young people. Int J Environ Res Public Health. 2017 Feb;14(2). pii: E208. doi: 10.3390/ijerph14020208.

46. Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, …, Vajdic C, et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun. 2017 Feb;8:14175. doi: 10.1038/ncomms14175.

47. Möller H, Falster K, Ivers R, Falster MO, Clapham K, Jorm L. Closing the Aboriginal child injury gap: targets for injury prevention. Aust N Z J Public Health. 2017 Feb;41(1):8-14. doi: 10.1111/1753-6405.12591. [Epub 2016 Oct 23].

48. Blanch B, Gladstone E, Smolina K, Buckley NA, Karanges EA, Morgan SG, Pearson, SA. Benchmarking prescription drug access patterns in pharmaceutical claims: a method for identifying high and potentially harmful opioid use in Australia and Canada? JPHSR. 2017 Jan;8(1):23-30. doi.org/10.1111/jphs.12165

49. Daniels B, Lord SJ, Kiely BE, Houssami N, Haywood P, Lu CY, Ward RL, Pearson SA, et al. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort. BMJ Open. 2017 Jan;7(1)e014439. doi: 10.1136/bmjopen-2016-014439.

50. Slewa-Younan S, Guajardo MGU, Yaser A, Mond J, Smith M, Milosevic D, …, Lujic S, et al. Causes of and risk factors for posttraumatic stress disorder: The beliefs of Iraqi and Afghan refugees resettled in Australia. Int J Ment Health Syst. 2017 Jan;11:4. doi: 10.1186/s13033-016-0109-z. eCollection 2017.

51. Nelson A, Vajdic CM, Ashton LJ, Le Marsney RE, Nivison-Smith I, Wilcox L, Dodds AJ, O’Brien TA. Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non-malignant diseases. Pediatric Blood Cancer. 2017;64:197-202.

Published Abstracts

1. Brodaty H, Heffernan M, Fiatorone Singh M, Valenzuela M, Andrews G, Lautenschlager NT, et al. Maintain Your Brain: A Randomised Controlled Trial of an Internet-Based Multi-Component Lifestyle Intervention to Prevent Cognitive Decline and Dementia [Abstract F4-05-01]. Alzheimer’s Association International Conference (AAIC) 2017. London, UK: Elsevier; 2017. p. P1216-P.

2. Tervonen HE, Chen TY, Moylan E, Della-Fiorentina SA, Boyle F, Beith J, et al. Risk of Emergency Hospitalisation Following Adjuvant Chemotherapy for Early Breast Cancer in NSW. Asia-Pacific Journal of Clinical Oncology. 2017; p171

3. Daniels B, Houssami N, Lord SJ, Kiely BE, Pearson SA. Did a policy to ease the prescribing restrictions for lapatinib (L) as second-line HER2-positive metastatic breast cancer (HER2+MBC) increase initiation rates? Pharmacoepidemiology and Drug Safety; 2017. 26(S2);p19 abstract 27. DOI: 10.1002/pds.4275.

4. Gisev N, Pearson SA, Karanges EA, Larance B, Buckley NA, Larney S, Dobbins T, Blanch B, Degenhardt L. To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia? Pharmacoepidemiology and Drug Safety; 2017. 26(S2); p106 abstract 171. DOI: 10.1002/pds.4275.

5. Schaffer A, Buckley NA, Dobbins T, Degenhardt L, Larance B, Pearson SA. Opioid switching after introduction of a tamper-resistant oxycodone formulation in Australia: a population-based study. Pharmacoepidemiology and Drug Safety; 2017. 26(S2);p212 abstract 351. DOI: 10.1002/pds.4275.

6. Raichand S, Pearson SA, Buckley NA, Havard A. Estimating the average daily dose of teratogenic medicines dispensed to women of child-bearing age. Pharmacoepidemiology and Drug Safety; 2017. 26(S2);p417 abstract 692. DOI: 10.1002/pds.4275.

7. Schaffer A, Buckley N, Pearson SA. Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy: a population-based study (2005-2015). Pharmacoepidemiology and Drug Safety; 2017. 26(S2);p519 abstract 859. DOI: 10.1002/pds.4275.


182017

Government and Industry Reports 2017

1. Falster KA, Hanly M. Early life pathways into child protection and child development outcomes at age five: Findings from a population-based data linkage study (The Seeding Success Study). 2017 2017/09/27/.

2. Falster MO, Jorm L. A guide to the potentially avoidable deaths indicator in Australia. 2017 2017/03/15/. Report No.: 978-1-925224-77-1.

3. Falster MO, Jorm L. A guide to the potentially preventable hospitalisations indicator in Australia. 2017 2017/03/15/. Report No.: 978-1-925224-76-4.

4. Fitzgerald O, Harris K, Paul RC, Chambers GM. Assisted reproductive technology in Australia and New Zealand 2015. Sydney: UNSW Sydney; 2017 2017/10/13/. Report No.: 978-0-7334-3761-8.

5. Hanly M, Falster KA. Early life health, development and pathways into child protection for children placed in residential care: Findings from a population-based data linkage study (The Seeding Success Study). 2017 2017/10/25/.

6. Moeller H, Hanly M, Jorm L, Falster KA. Emergency department visits and hospital admissions for injury in children who participated in the Brighter Futures program: a population-based data linkage study. 2017 2017/02/28/.

7. Tran DT, Raichand S, Havard A, Jorm L. Rapid environmental scan and literature review on avoidable hospital readmission indicators. 2017 2017/06/30/.

8. Vajdic C, Pearson S. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in Australia: A review of existing data sources to estimate incidence and risk factors. Report to the Therapeutic Goods Administration March 2017.

9. Zoega H, Daniels B, Litchfield M, Pearson S. Review of the literature and current utilisation of PBS-listed Proton Pump Inhibitors (PPIs) to treat gastrointestinal acid related disorders. Report to Commonwealth Department of Health October 2017.

10. Zoega H, Schaffer A, Litchfield M, Pearson S. Post-market review of pulmonary arterial hypertension medicines. Report to Commonwealth Department of Health November 2017.


192017

Invited conference presentations 20171. Chambers GM. ANZARD Update, a New Era. Fertility Society of Australia Annual Scientific Meeting,

Perth, October 15-18th 2017 [Invited Speaker].

2. Chambers GM. Assisted Reproductive Technology Registries: a force for good and evil. Monash IVF Clinical Education Symposium. Melbourne March 24 2017 [Invited Speaker].

3. Chambers GM. The economics of assisted reproductive technologies; and international perspective. International Gynaecologic Society 2017 Congress, Sydney March 23 2017 [Invited Speaker].

4. Chambers GM. Measuring treatment outcomes of assisted reproductive technologies. Reproductive Technology Council Seminar, Western Australian Department of Health. February 2017 [Invited Speaker].

5. Jorm LR. Using big data from linked health records to improve cardiovascular care. Sydney Cardiovascular Symposium, 2017 [Invited plenary speaker].

6. Jorm LR. Big data applications for devices in Australia. MDEpiNet Annual Meeting, Washington USA, 2017 [Invited speaker].

7. Jorm LR. Big data in health and medicine: issues and challenges. Government of Hong Kong Health Research Symposium, Hong Kong, 2017 [Invited keynote speaker].

8. Jorm LR. Data sharing: Building trust, partnerships and infrastructure. Symposium: Optimising the use of administrative data for respiratory infection research. Wesfarmers Centre of Vaccines and Infectious Diseases, Perth, 2017 [Invited speaker].

9. Jorm LR. Utilizing big data for patient-centered healthcare in Australia. NECA – National Evidence-based healthcare Collaborating Agency Annual Conference, Seoul, South Korea, 2017 [Invited keynote speaker].

10. Pearson S. Big data for Australian pharmaceutical policy research: Is the glass half empty or half full? St Michael’s Hospital, June 2017 [Invited keynote speaker]

11. Pearson S. The good, the bad and the ugly: The state of play in Australian pharmacoeidemiology research. International Society of Pharmacoepidemiology, University of Toronto, June 2017 [Invited keynote speaker]

12. Pearson S. Big Data Down Under: Implications for Pharmaceutical Policy Research, CHSPER, University of British Columbia. June 2017.

13. Pearson S. DUR-informing and evaluating policy. Asian Conference on Pharmacoepidemiology. Brisbane, Australia. October 2017. [Invited keynote speaker]

Documents

Centre for Big Data Research in Health Annual …...Centre for Big Data Research in Health, UNSW Sydney 2017 1 Director’s message I am pleased to share with you the achievements